Trial of Methylphenidate and Thioridazine

Abstract

A double-blind, placebo-controlled, cross-over study of methylphenidate (0.4 mg/kg/day) and thioridazine (1.75 mg/kg/day) in 27 intellectually subaverage children is reported from The Nisonger Center for Mental Retardation and Developmental Disabilities, Ohio State Univ., Columbus, OH, and the University of Aukland, New Zealand.

Keywords

• methylphenidate
• omission errors
• cognitive-motor performance tests